viewRhythm Biosciences Ltd

Rhythm Biosciences signs The Alfred Hospital for ColoSTAT clinical test

ColoSTAT has the potential to play an important role in reducing morbidity and mortality rates associated with colorectal cancer.

Rhythm's lead product ColoSTAT is a low-cost blood test for the early detection of bowel cancer

Rhythm Biosciences Ltd (ASX:RHY) has signed The Alfred Hospital in Melbourne as its third clinical trial site for ColoSTAT®, the lifesaving blood test for the early detection of colorectal cancer.

Associate Professor and Head of Endoscopy at the hospital, Gregor Brown, has been appointed as the site’s principal investigator for the trial.

Brown is well recognised for his research into improving colonoscopy techniques including polyp removal during colonoscopy and balloon enteroscopy as well for the development of new treatments for coeliac and inflammatory bowel diseases.

Shares are up more than 6% today to 17.5 cents.

“Deep expertise in colonoscopic research”

Rhythm chief executive officer Glenn Gilbert said: “The Alfred Hospital has a long history of supporting clinical trials and a deep expertise in colonoscopic research.

“Working with The Alfred adds to the credibility of this clinical trial and we look forward to this collaboration and ultimately the results.”

Recruitment for the trial is expected to reach around 1,000 patients and will be completed at the end of 2019.

The trial will form a key component for both CE Mark & TGA registration as well as approval to market ColoSTAT in Australia and Europe in 2020.

READ: Rhythm Bioscience welcomes new ColoSTAT trial member in Monash Health

The company continues to work with global parties on the most effective assay development, optimisation and clinical utility of the reagents that will form the core components to the final ColoSTAT test.

Rhythm Bioscience also expects to welcome further hospitals to the ColoSTAT trial in the coming months.

Quick facts: Rhythm Biosciences Ltd

Price: 0.08 AUD

Market: ASX
Market Cap: $14.11 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Castillo Copper begins trading in London after raising £1.3mln

Castillo Copper's (LON:CCZ)(ASX:CCZ) Ged Hall speaks to Proactive's Polly Middlehurst as the explorer began trading in London. Castillo's focused on resource exploration projects that have the potential, through the application of disciplined and structured exploration and analysis, to be...

11 hours, 6 minutes ago

2 min read